Ferrer inCode. Pioneers in biohealth
Our diagnostic tools are the result of our own research and development or our alliances and agreements.
Ferrer inCode is a new company emerging from a strategic alliance between Ferrer, a group of more than 39 companies, that operates in Pharmaceuticals, Fine Chemicals and Food sectors, three crucial areas to contribute to the improvement of people's health and quality of life, and Gendiag S.L., a young company with a multidisciplinary staff working in a range of fields from pharmaceutical to biotech industry, with the view to make personalized medicine available for the benefit of society at large, setting up genetic diagnostic tools.
Ferrer has its origin in 1959 with the foundation of Laboratorios Ferrer S.L., and has as a mission. A greater involvement with the present to make a better future. And above all, to continue being what we are: a great group of people able to listen, learn and act accurately and with an overall perspective.
Gendiag was established in February 2006 with a mission to turn the opportunities coming from projects developed in the scholar scientific world and in biotech companies into products and services, that will help health professionals to significantly improve prevention, therapeutic targets and quality of life of patients suffering from highly prevalent and costly diseases.
Ferrer inCode's vision is to turn innovative biotechnological projects into products and services, that will help health professionals to significantly improve the prevention of diseases, therapeutic targets, and then the quality of life of patients suffering from highly prevalent illnesses such as oncological, cardiovascular and CNS diseases.
To develop all of this Ferrer inCode works in collaboration with chemical-pharmaceutical and biotech companies in R&D and innovation programs of new products and services.
Ferrer inCode,, will promote and grant access to personalized medicine through services of diagnosis , prognosis and prediction based mainly in genomics, proteomics, metabolomics and bioinformatics technology.
Thanks to the Human Genome Project the sequence of the nucleotides which compose the human genome and the sequences of DNA,has been determined this has allowed us to identify the different human genes. Genomics studies the structure and activity of the genes. A step ahead we find proteomics, that is, the study of the proteins codified and expressed by each one of the genes at any time and under specific determined conditions of time and environment. It's very important To know the proteins that are expressed in each case since they are responsible for multiple biological structural or enzymatic functions (biological reactions). proteins can experience numerous modifications when exposed to different microenvironments. These modifications in the expression of one or several proteins may have influences on the individual. Finally A closer approach to what occurs in the body is metabolomics. This is the study of the biochemical reactions that take place in the cells and tissues of the individuals. The study of the metabolomic profile allows us to know the thousands of molecules which are the products of the metabolism and thus to analyze the biochemical pathways and to identify, for example, biomarkers of different diseases in order to establish earlier and more accurate diagnoses, or the prognosis of therapeutic responses as well as toxicity to drugs. All of this must be integrated and analyzed through Bioinformatics. This consists on specific mathematical programs that administrate, analyze and allow us to comprehend different data, thus giving us an answer to the biological questions relative to the genomic, proteomic and metabolomic studies..
Through the application of these new technologies to everyday clinical practice, Ferrer inCode commits to serve society improving health. As the knowledge in these fields is rapidly increasing, the range of services will soon be wider in order to obtain a greater and better personalization of the health care.